Flortaucipir-PET SUVR
2 papers2 findings
- Human trial1
- Humans1
Upstream
1Clinical Dementia Rating
upin humans1
1 study
Clinical Dementia Rating
upin humans1
Clinical Dementia Rating increases Flortaucipir-PET SUVR in humans (25.5% vs 13.3%).
“In the CDR0 and the CDR0.5 subgroups, 13.3% and 25.5% of participants, respectively, were tau positive (SUVR > 1.11”
Human trialpreclinical AD with CDR-GS 0.5 vs CDR-GS 0
AAIC 2025 abstract25 Dec 2025
Associations
1Temporal lobe
upin humans1
1 study
Temporal lobe
upin humans1
Temporal lobe is associated with Flortaucipir-PET SUVR in humans (1.22-1.25 medial temporal vs 1.03-1.07 frontal).
“The medial and lateral temporal lobes had the highest regional baseline SUVRs for both subgroups.”
Human trialpreclinical AD
AAIC 2025 abstract25 Dec 2025
Latest
2 in 12 monthsAAIC 2025 Abstract
Predicting longitudinal accumulation of tau pathology in pre‐clinical population using machine learning: Data from the A4 and LEARN Studies
Cohort study of 360 peopleBiomarkers
AAIC 2025 Abstract
Flortaucipir patterns in preclinical Alzheimer's disease: an evaluation of TRAILBLAZER‐ALZ 3 baseline data
Randomised trial in 310 peopleAlzheimer's disease